Teva Pharmaceutical Industries (TEVA) Operating Expenses (2017 - 2026)

Teva Pharmaceutical Industries' Operating Expenses history runs 10 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• Quarterly Operating Expenses rose 83.82% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 363.95% YoY) and the FY2025 annual result came in at $4.0 billion, up 84.02% from the prior year.
• Operating Expenses was $1.0 billion for Q1 2026 at Teva Pharmaceutical Industries, down from $2.3 billion in the prior quarter.
• Across five years, Operating Expenses topped out at $2.3 billion in Q4 2025 and bottomed at -$591.0 million in Q4 2024.
• A 5-year average of $822.5 million and a median of $842.0 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2024 — Operating Expenses slumped 131.07% — and 2025, when it surged 490.36%.
• Teva Pharmaceutical Industries' Operating Expenses stood at $837.0 million in 2022, then soared by 127.24% to $1.9 billion in 2023, then plunged by 131.07% to -$591.0 million in 2024, then jumped by 490.36% to $2.3 billion in 2025, then slumped by 56.65% to $1.0 billion in 2026.
• Business Quant data shows TEVA's Operating Expenses at $1.0 billion in Q1 2026, $2.3 billion in Q4 2025, and $573.0 million in Q3 2025.